Mylan has announced that US regulators are going to reject its generic version of GlaxoSmithKline’s asthma/COPD inhaler Advair Diskus.
News
ViiV’s two-drug HIV regimen hits PhIII targets
ViiV Healthcare’s two-drug HIV regimen of Tivicay and Epivir has hit targets in late-stage trials, showing non-inferiority to a three-drug regimen and thus the potential to offer patients an alternative treatment strategy.
New funding to digitise info between health and social care
NHS Digital has announced new funding to facilitate digitising the flow of information between adult social care and health services.
Brexit Health Alliance calls for co-operation on infectious diseases
The Brexit Health Alliance is warning that efforts to prevent the spread of infectious diseases in the UK could be under threat if the country pulls out of the EU’s early warning system without having a suitable replacement.
Public backs NHS spending increases
An “overwhelming majority” of people support increasing spending on health and social care services, indicates a poll of 1,000 adults across Britain undertaken by Ipsos Mori for the NHS Confederation.
Gruenenthal launches PhIII trials of neridronate for rare pain disorder
Gruenenthal has kicked off two pivotal Phase III trials investigating the bisphosphonate neridronate for the treatment of Complex Regional Pain Syndrome (CRPS).
NHS should employ robots to save time and money, suggests finds
The NHS could free up frontline time worth up to £12.5 billion a year by fully embracing automation, such as employing robots at the bed side and care bots in the home, according to a new report led by former health minister Lord Darzi.
FDA OKs MSD’s Keytruda for advanced cervical cancer
US regulators have given MSD’s Keytruda its first regulatory approval for a gynaecological cancer.
AZ, Lilly pull plug on Alzheimer’s disease trials
Alzheimer’s disease research has taken another hit with the failure of AstraZeneca and Eli Lilly’s experimental BACE inhibitor lanabecestat.
CR UK tests Asterias’ novel lung cancer immunotherapy jab
Cancer Research UK has begun testing a novel immunotherapy vaccine for lung cancer in Phase I trials, under a collaboration agreement with Asterias Biotherapeutics.
SMC approves funding for six new therapies on the NHS
The Scottish Medicines Consortium has approved NHS funding for six new therapies, offering patients new options for leukaemia, epilepsy, lung cancer, plaque psoriasis, and carcinoid syndrome-related diarrhea.
Allergan’s experimental migraine drug hits trial targets
Allergan says its CGRP receptor antagonist atogepant has hit its primary target in a Phase IIb/III trial assessing its efficacy in preventing episodic migraine.
Researchers to trial prostate cancer saliva test
An international team of researchers, led by scientists at The Institute of Cancer Research, London, are planning to trial a novel saliva-based DNA test designed to predict men at risk of developing prostate cancer.
Huddersfield Uni launches pharma policy and practice research centre
The University of Huddersfield has launched the Centre for Pharmaceutical Policy and Practice Research, tasked with keeping the industry “armed with the latest research methods and advice”.
EU approves first-line use of AZ’ Tagrisso in lung cancer
AstraZeneca’s Tagrisso has been given a green light in Europe for first-line use to treat EGFR-mutated non-small cell lung cancer (NSCLC), offering a new line of attack at this stage of the disease.
